FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175489568> ?p ?o ?g. }

• W3175489568 abstract "Background: Lasmiditan, a serotonin 5-HT1F receptor agonist, was effective for acute treatment of patients with migraine in phase 2 studies. We aimed to replicate these findings in a population that includes patients with migraine and cardiovascular risks. Methods: This prospective, double-blind, phase 3 multicentre study randomly assigned patients with migraine with and without aura (1:1:1:1 ratio) to oral lasmiditan 200 mg, 100 mg, 50 mg, or placebo. Patients were instructed to dose at home within 4 h of onset of migraine attack of at least moderate intensity and not improving. The primary objective was to assess the proportion of patients' headache pain-free and most bothersome symptom (MBS)-free at 2 h post-dose for each dose of lasmiditan versus placebo (NCT02605174). Findings: Patients (n=3005) were assigned and treated (n=2583, safety population): 1938 lasmiditan (200 mg n=528, 100 mg n=532, and 50 mg n=556 included in primary analysis) and 645 placebo (540 included in primary analysis) Most patients (79·2%) had ≥1 cardiovascular risk factor at baseline, in addition to migraine. Lasmiditan was associated with significantly more pain freedom at 2 h (lasmiditan 200 mg: 38·8%, OR 2·3, 95% CI 1·8-3·1, p<0·001; 100 mg: 31·4%, OR 1·7, 1·3-2·2, p<0·001; 50 mg: 28·6%, OR 1·5, 1·1-1·9, p=0·003 versus placebo 21·3%) and freedom from MBS at 2 h (lasmiditan 200 mg: 48·7%, OR 1·9, 95% CI 1·4-2·4, p<0·001; 100 mg: 44·2%, OR 1·6, 1·2-2·0, p<0·001; 50 mg: 40·8%, OR 1·4, 1·1-1·8, p=0·009 versus placebo 33·5%). Treatment-emergent adverse events were reported in 253 of 649 (39·0%), 229 of 635 (36·1%), and 166 of 654 (25·4%) of patients on lasmiditan 200, 100, and 50 mg, respectively, versus 75 of 645 (11·6%) on placebo. Most adverse events were CNS-related and included dizziness, somnolence, and paresthesia. Interpretation: Lasmiditan was effective at 2-h post-dose for acute treatment of migraine at all oral doses tested. Efficacy and safety was consistent with another phase 3 study. Clinical Trial Number: This study is registered with ClinicalTrials.gov, number NCT02605174. Funding Statement: CoLucid Pharmaceuticals and Eli Lilly and Company. Declaration of Interests: PJG reports grants and personal fees from Amgen and Eli-Lilly and Company, and personal fees from Alder Biopharmaceuticals, Allergan, Autonomic Technologies Inc., Dr Reddy's Laboratories, Electrocore LLC, eNeura, Novartis, Scion, Teva Pharmaceuticals, and Trigemina Inc., and personal fees from MedicoLegal work, Up-to-Date, Oxford University Press, Massachusetts Medical Society, and Wolters Kluwer; and a patent Magnetic stimulation for headache assigned to eNeura without fee. AW, ED, MGC, and SKA are full time employees and minor stockholders for Eli Lilly and Company. BK was a full-time employee and minor stockholder for CoLucid Pharmaceuticals when the study was designed and conducted. CG has received honoraria for consulting and lectures within the past three years from Allergan Pharma, Ratiopharm, Boehringer Ingelheim Pharma, Lilly Germany, Novartis Pharma, Desitin Arzneimittel, Cerbotec, Bayer vital, Hormosan Pharma, electroCore, Grunenthal, Reckitt Benckiser, and TEVA. He does not hold any stocks of pharmaceutical companies or medical device companies. Ethics Approval Statement: The study was approved by the authorities and independent ethics committees. This study was conducted in accordance with the Declaration of Helsinki and internationally accepted standards of Good Clinical Practice. All patients gave written informed consent before enrollment. Protocol Number COL MIG-302." @default.
• W3175489568 created "2021-07-05" @default.
• W3175489568 creator A5004525209 @default.
• W3175489568 creator A5008785455 @default.
• W3175489568 creator A5012170627 @default.
• W3175489568 creator A5059017023 @default.
• W3175489568 creator A5069865671 @default.
• W3175489568 creator A5084460133 @default.
• W3175489568 creator A5089812265 @default.
• W3175489568 date "2018-01-01" @default.
• W3175489568 modified "2023-09-24" @default.
• W3175489568 title "Efficacy and Tolerability of Lasmiditan, an Oral 5-HT1F Receptor Agonist, for the Acute Treatment of Migraine: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study" @default.
• W3175489568 doi "https://doi.org/10.2139/ssrn.3228912" @default.
• W3175489568 hasPublicationYear "2018" @default.
• W3175489568 type Work @default.
• W3175489568 sameAs 3175489568 @default.
• W3175489568 citedByCount "0" @default.
• W3175489568 crossrefType "journal-article" @default.
• W3175489568 hasAuthorship W3175489568A5004525209 @default.
• W3175489568 hasAuthorship W3175489568A5008785455 @default.
• W3175489568 hasAuthorship W3175489568A5012170627 @default.
• W3175489568 hasAuthorship W3175489568A5059017023 @default.
• W3175489568 hasAuthorship W3175489568A5069865671 @default.
• W3175489568 hasAuthorship W3175489568A5084460133 @default.
• W3175489568 hasAuthorship W3175489568A5089812265 @default.
• W3175489568 hasConcept C126322002 @default.
• W3175489568 hasConcept C142724271 @default.
• W3175489568 hasConcept C170493617 @default.
• W3175489568 hasConcept C197934379 @default.
• W3175489568 hasConcept C204787440 @default.
• W3175489568 hasConcept C27081682 @default.
• W3175489568 hasConcept C2777350023 @default.
• W3175489568 hasConcept C2778375690 @default.
• W3175489568 hasConcept C2778541695 @default.
• W3175489568 hasConcept C2778871607 @default.
• W3175489568 hasConcept C2778938600 @default.
• W3175489568 hasConcept C2908647359 @default.
• W3175489568 hasConcept C42219234 @default.
• W3175489568 hasConcept C71924100 @default.
• W3175489568 hasConcept C99454951 @default.
• W3175489568 hasConceptScore W3175489568C126322002 @default.
• W3175489568 hasConceptScore W3175489568C142724271 @default.
• W3175489568 hasConceptScore W3175489568C170493617 @default.
• W3175489568 hasConceptScore W3175489568C197934379 @default.
• W3175489568 hasConceptScore W3175489568C204787440 @default.
• W3175489568 hasConceptScore W3175489568C27081682 @default.
• W3175489568 hasConceptScore W3175489568C2777350023 @default.
• W3175489568 hasConceptScore W3175489568C2778375690 @default.
• W3175489568 hasConceptScore W3175489568C2778541695 @default.
• W3175489568 hasConceptScore W3175489568C2778871607 @default.
• W3175489568 hasConceptScore W3175489568C2778938600 @default.
• W3175489568 hasConceptScore W3175489568C2908647359 @default.
• W3175489568 hasConceptScore W3175489568C42219234 @default.
• W3175489568 hasConceptScore W3175489568C71924100 @default.
• W3175489568 hasConceptScore W3175489568C99454951 @default.
• W3175489568 hasLocation W31754895681 @default.
• W3175489568 hasOpenAccess W3175489568 @default.
• W3175489568 hasPrimaryLocation W31754895681 @default.
• W3175489568 hasRelatedWork W1486754956 @default.
• W3175489568 hasRelatedWork W1490608490 @default.
• W3175489568 hasRelatedWork W1534295045 @default.
• W3175489568 hasRelatedWork W1537760222 @default.
• W3175489568 hasRelatedWork W1942412490 @default.
• W3175489568 hasRelatedWork W2067490438 @default.
• W3175489568 hasRelatedWork W2167861291 @default.
• W3175489568 hasRelatedWork W2330518110 @default.
• W3175489568 hasRelatedWork W2550916925 @default.
• W3175489568 hasRelatedWork W2565667106 @default.
• W3175489568 hasRelatedWork W2566572805 @default.
• W3175489568 hasRelatedWork W2608751463 @default.
• W3175489568 hasRelatedWork W2755354212 @default.
• W3175489568 hasRelatedWork W2791532518 @default.
• W3175489568 hasRelatedWork W2799833870 @default.
• W3175489568 hasRelatedWork W2805067797 @default.
• W3175489568 hasRelatedWork W2968435022 @default.
• W3175489568 hasRelatedWork W3081998503 @default.
• W3175489568 hasRelatedWork W3158921308 @default.
• W3175489568 hasRelatedWork W1879803731 @default.
• W3175489568 isParatext "false" @default.
• W3175489568 isRetracted "false" @default.
• W3175489568 magId "3175489568" @default.
• W3175489568 workType "article" @default.